Literature DB >> 21734726

Comparative analysis of FV vectors with human α- or β-globin gene regulatory elements for the correction of β-thalassemia.

I Morianos1, E K Siapati, G Pongas, G Vassilopoulos.   

Abstract

β-Globin locus control region (LCR) sequences have been widely used for the regulated expression of the human β-globin gene in therapeutic viral vectors. In this study, we compare the expression of the human β-globin gene from either the HS2/HS3 β-globin LCR or the HS40 regulatory element from the α-globin locus in the context of foamy virus (FV) vectors for the genetic correction of β-thalassemia. Both regulatory elements expressed comparable levels of human β-globin in a murine erythroleukemic line, whereas in murine hematopoietic stem cells the HS40.β vector proved more efficient in β-globin expression and correction of the β-thalassemia phenotype. Following transplantation in the Hbb(th3/+) mouse model, the expression efficiency by the two vectors was similar, whereas the HS40.β vector achieved relatively more stable transgene expression. In addition, in an ex vivo assay using CD34+ cells from thalassemic patients, both vectors achieved significant human β-globin expression and restoration of the thalassemic phenotype as evidenced by enhanced erythropoiesis and decreased apoptosis. Our data suggest that FV vectors with the α-globin HS40 element can be used as alternative but equally efficient vehicles for human β-globin gene expression for the genetic correction of β-thalassemia.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21734726     DOI: 10.1038/gt.2011.98

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  8 in total

1.  Advances in foamy virus vector technology and disease correction could speed the path to clinical application.

Authors:  Els Verhoeyen
Journal:  Mol Ther       Date:  2012-06       Impact factor: 11.454

2.  Foamy Virus Vector Carries a Strong Insulator in Its Long Terminal Repeat Which Reduces Its Genotoxic Potential.

Authors:  Michael Aaron Goodman; Paritha Arumugam; Devin Marie Pillis; Anastacia Loberg; Mohammed Nasimuzzaman; Danielle Lynn; Johannes Christiaan Maria van der Loo; Phillip Joseph Dexheimer; Mehdi Keddache; Thomas Roy Bauer; Dennis Durand Hickstein; David William Russell; Punam Malik
Journal:  J Virol       Date:  2017-12-14       Impact factor: 5.103

3.  Correction of β-thalassemia by CRISPR/Cas9 editing of the α-globin locus in human hematopoietic stem cells.

Authors:  Giulia Pavani; Anna Fabiano; Marine Laurent; Fatima Amor; Erika Cantelli; Anne Chalumeau; Giulia Maule; Alexandra Tachtsidi; Jean-Paul Concordet; Anna Cereseto; Fulvio Mavilio; Giuliana Ferrari; Annarita Miccio; Mario Amendola
Journal:  Blood Adv       Date:  2021-03-09

4.  Best Practices in qPCR and dPCR Validation in Regulated Bioanalytical Laboratories.

Authors:  Amanda Hays; Rafiq Islam; Katie Matys; Dave Williams
Journal:  AAPS J       Date:  2022-02-22       Impact factor: 4.009

Review 5.  Gene therapy for hemoglobinopathies: the state of the field and the future.

Authors:  Shanmuganathan Chandrakasan; Punam Malik
Journal:  Hematol Oncol Clin North Am       Date:  2014-04       Impact factor: 3.722

6.  Long-term follow-up of foamy viral vector-mediated gene therapy for canine leukocyte adhesion deficiency.

Authors:  Thomas R Bauer; Laura M Tuschong; Katherine R Calvo; Heather R Shive; Tanya H Burkholder; Eleanor K Karlsson; Robert R West; David W Russell; Dennis D Hickstein
Journal:  Mol Ther       Date:  2013-03-26       Impact factor: 11.454

7.  Gene therapy model of X-linked severe combined immunodeficiency using a modified foamy virus vector.

Authors:  Satoshi Horino; Toru Uchiyama; Takanori So; Hiroyuki Nagashima; Shu-Lan Sun; Miki Sato; Atsuko Asao; Yoichi Haji; Yoji Sasahara; Fabio Candotti; Shigeru Tsuchiya; Shigeo Kure; Kazuo Sugamura; Naoto Ishii
Journal:  PLoS One       Date:  2013-08-21       Impact factor: 3.240

Review 8.  FV Vectors as Alternative Gene Vehicles for Gene Transfer in HSCs.

Authors:  Emmanouil Simantirakis; Ioannis Tsironis; George Vassilopoulos
Journal:  Viruses       Date:  2020-03-19       Impact factor: 5.048

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.